Jagsonpal Pharmaceuticals (JAGSNPHARM) Q1 26/27 earnings summary

Executive summary

• Q1 FY27 revenue grew 9% year-over-year to ₹822.32 million, driven by strong brand performance and higher medical representative productivity, outpacing industry growth rates.

• Operating EBITDA increased 21% YoY to ₹191 million, with margin expansion to 23.2%.

• PAT rose 22% YoY to ₹132 million, with margin improvement to 16%.

• Completed acquisition of 85% stake in Aequitas Healthcare for ₹208 million, providing immediate entry into the hospital segment.

• Completed ₹400 million share buyback at a 40% premium, improving ROCE by 340 basis points.

Financial highlights

• Revenue from operations rose 9% YoY to ₹822.32 million; gross profit increased over 10% to ₹540 million, with gross margins above 65%.

• Operating EBITDA grew 21% to ₹191 million, with margins at 23.2%, up 240 basis points.

• PAT increased 22% to ₹132 million, with margins improving by 176 basis points to 16%.

• Strong operating cash generation maintained a closing cash balance of ₹1,700 million.

• Basic EPS for the quarter was ₹2.00, up from ₹1.60 YoY.

Outlook and guidance

• Targeting revenue growth at 1.5x the Indian pharma industry rate, with continued focus on organic and inorganic expansion.

• Aequitas expected to reach ₹1,000 million revenue and ₹100 million EBITDA within 2.5 years.

• Ongoing focus on productivity, brand building, and premiumization to drive margin expansion.

• Evaluating impact of new Code of Wages (Central) Rules, 2026, for future accounting.